This listing of claims will replace all prior versions, and listings, of claims in the application:

Listing of Claims:

1. (Currently amended) A compound of the Formula I



Formula I

wherein:

R_1 is $(CH_2)_mCH_3$ where m is 0 or an integer in the range from 1 to 16, or an alkenyl, alkynyl, alkoxy, alkylthio, or alkyl sulfinyl group having from 2 to 17 carbon atoms, wherein R_1 may be optionally substituted with one or more substituents selected from hydroxy, aldehyde, oxo, lower acyloxy, halogen, thio, sulfoxide and sulfone,

R_2 ((=)) is H, CH_3 or CH_2CH_3,

R_3 ((=)) is H or CH_3,

R_4 ((=)) is H or CH_3,

~~R_5 = lower alkyl having from 1 to 5 carbon atoms,~~

n is an integer in the range from 1 to 3,

~~and~~ X is carboxyl (COOH), ~~or~~ carbalkoxy ($COOR_5$)~~, cyano (C≡N), phosphonic acid (PO_3H_2), phosphonate ester ($PO_3[R_5]_2$)~~ or 5-tetrazole,

R_5 is lower alkyl having from 1 to 5 carbon atoms, and

R_1, R_2 and R_3 are each different so that the carbon atom to which they are attached is chiral and the compound of Formula I is ~~as~~ a substantially pure enantiomer in the R or S configuration or a pharmaceutically acceptable salt thereof.

2. (Currently amended) A compound of the Formula I according to claim 1 wherein:

R_1 ((=)) is $(CH_2)_mCH_3$ where m is 0 or an integer in the range from 1 to 16,

R_2 ((=)) is CH_3,

R_3 ((=)) is H,

R_4 ((=)) is H or CH_3,

~~R_5 = lower alkyl having from 1 to 5 carbon atoms,~~

n is an integer in the range from 1 to 3,

~~and~~ X is carboxyl (COOH), ~~or~~ carbalkoxy ($COOR_5$)~~, cyano (C=N), phosphonic acid (PO_3H_2), phosphonate ester ($PO_3[R_5]_2$)~~ or 5-tetrazole, and

R_5 is lower alkyl having from 1 to 5 carbon atoms,

or a pharmaceutically acceptable salt thereof.

3. (Currently amended) A compound of the Formula I according to claim 1 wherein:

R_1 ((=)) is $(CH_2)_mCH_3$ where m is 0 or an integer in the range from 1 to 16,

R_2 ((=)) is CH_3,

R_3 ((=)) is H,

R_4 ((=)) is H or CH_3,

~~R_5 = lower alkyl having from 1 to 5 carbon atoms~~,

n is an integer in the range from 1 to 3,

~~and~~ X is carboxyl (COOH), ~~or~~ carbalkoxy ($COOR_5$)~~ cyano (C=N), phosphonic acid (PO_3H_2), phosphonate ester ($PO_3[R_5]_2$)~~ or 5-tetrazole, and

R_5 is lower alkyl having from 1 to 5 carbon atoms,

as a substantially pure enantiomer in the R-configuration, or a pharmaceutically acceptable salt thereof.

4. (Currently amended) A compound of the formula I according to claim 1 wherein:

R_1 ((=)) is $(CH_2)_mCH_3$ where m is 0 or an integer in the range from 1 to 16,

R_2 ((=)) is CH_3,

R_3 ((=)) is H,

R_4 ((=)) is H or CH_3,

~~R_5 = lower alkyl having from 1 to 5 carbon atoms,~~

n is an integer in the range from 1 to 3,

~~and~~ X is carboxyl (COOH), ~~or~~ carbalkoxy ($COOR_5$) ~~cyano (C≡N), phosphonic acid (PO_3H_2), phosphonate ester ($PO_3[R_5]_2$)~~ or 5-tetrazole, and

R_5 is lower alkyl having from 1 to 5 carbon atoms,

as a substantially pure enantiomer in the S-configuration, or a pharmaceutically acceptable salt thereof.

5. (Currently amended) A compound according to claim 3, wherein said compound of formula I is selected from the group consisting of:

(R)-3-(2-Heptylamino)propionic acid;

(R)-3-[N-(2-Heptyl)-N-methylamino]propionic acid;

Methyl (R)-3-(2-heptylamino)propionate;

Methyl (R)-3-[N-(2-heptyl)-N-methylamino]propionate;

~~(R)-2-(2-Pentylamino)acetonitrile;~~

~~(R)-2-(2-Pentylmethylamino)acetonitrile;~~

~~(R)-3-(2-Heptylamino)propionitrile;~~

~~(R)-3-(2-Heptylmethylamino)propionitrile;~~

~~(R)-2-(2-Pentylamino)ethanephosphonic acid;~~

~~(R)-2-(2-Pentylmethylamino)ethanephosphonic acid;~~ and

(R)-2-(2-Heptylamino)ethane-5-tetrazole.

6. (Currently amended) A compound according to claim 4, wherein said compound of formula I is selected from the group consisting of:

(S)-2-(2-Heptylamino)acetic acid;

(S)-2-[N-(2-Heptyl)-N-methylamino]acetic acid;

Methyl (S)-2-(2-heptylamino)acetate; and

Methyl (S)-2-[N-(2-Heptyl)-N-methylamino]acetate~~;~~

~~(S)-2-(2-Heptylamino)acetonitrile;~~

~~(S)-2-(2-Heptylmethylamino)acetonitrile;~~

~~(S)-2-(2-Heptylamino)ethanephosphonic acid; and~~

~~(S)-2-(2-Heptylmethylamino)ethanephosphonic acid~~.

7. (Currently amended) A compound selected from the group consisting of:

2-(1-Hexylmethylamino)acetic acid;

3-[N-(2-Propyl)-N-methylamino]propionic acid;

Methyl 2-[N-(2-propyl)-N-methylamino]acetate;

Methyl 2-[N-(1-hexyl)-N-methylamino]acetate; and

Methyl 3-[N-(1-hexyl)-N-methylamino]propionate~~;~~

~~2-(1-Hexylamino)acetonitrile;~~

~~2-(1-Hexylmethylamino)acetonitrile;~~

~~3-(3-Pentylamino)propionitrile;~~

~~3-(3-Pentylmethylamino)propionitrile;~~

~~2-(2-Propylamino)ethanephosphonic acid; and~~

~~2-(2-Propylmethylamino)ethanephosphonic acid~~.

8. (Previously amended) A compound according to claim 1 in the form of a hydrochloride salt.

9. (Previously amended) A compound according to claim 1 wherein m is an integer from 1 to 12.

10. (Previously amended) A compound according to claim 1 wherein m is an integer from 1 to 9.

11. (Currently amended) A composition for the treatment ~~or prevention~~ of a disease in which cell death occurs by apoptosis, which composition comprises an effective amount of a compound having the formula I as claimed in claim 1~~:~~



~~Formula I~~

~~wherein:~~

~~R_1 is $(CH_2)_mCH_3$ where m is 0 or an integer in the range from 1 to 16, or an alkenyl, alkynyl, alkoxy, alkylthio, or alkyl sulfinyl group having from 2 to 17 carbon atoms, wherein R_1 may be optionally substituted with one or more substituents selected from hydroxy, aldehyde, oxo, lower acyloxy, halogen, thio, sulfoxide and sulfone,~~

~~R_2 = H, CH_3 or CH_2CH_3,~~

~~R_3 = H or CH_3,~~

~~R_4 = H or CH_3~~

~~R_5 = lower alkyl having from 1 to 5 carbon atoms,~~

~~n is an integer in the range from 1 to 3,~~

~~and X is carboxyl (COOH), carbalkoxy ($COOR_5$), cyano (C=N), phosphonic acid (PO_3H_2), phosphonate ester ($PO_3[R_5]_2$) or 5-tetrazole,~~

~~as a substantially pure enantiomer in the R or S configuration or a pharmaceutically acceptable salt thereof,~~ in admixture with a suitable diluent or carrier.

12. (Currently amended) A composition according to claim 11, wherein:

R_1 is $(CH_2)_mCH_3$ where m is 0 or an integer in the range from 1 to 16,

R_2 ((=)) is CH_3,

R_3 ((=)) is H,

R_4 ((=)) is H or CH_3,

~~R_5 = lower alkyl having from 1 to 5 carbon atoms,~~

n is an integer in the range from 1 to 3,

~~and~~ X is carboxyl (COOH), carbalkoxy ($COOR_5$)~~, cyano (C≡N), phosphonic acid (PO_3H_2), phosphonate ester ($PO_3[R_5]_2$)~~ or 5-tetrazole, and

R_5 = lower alkyl having from 1 to 5 carbon atoms

~~or a pharmaceutically acceptable salt thereof, in admixture with a suitable diluent or carrier~~.

13. (Currently amended) A composition according to claim 11, wherein said compound of formula I is selected from the group consisting of:

(R)-3-(2-Heptylamino)propionic acid; and

(R)-3-[N-(2-Heptyl)-N-methylamino]~~)~~propionic acid;

Methyl (R)-3-(2-heptylamino)propionate;

Methyl (R)-3-[N-(2-Heptyl)-N-methylamino]~~)~~propionate;

~~(R)-2-(2-Pentylamino)acetonitrile;~~

~~(R)-2-(2-Pentylmethylamino)acetonitrile;~~

~~(R)-3-(2-Heptylamino)propionitrile;~~

~~(R)-3-(2-Heptylmethylamino)propionitrile;~~

~~(R)-2-(2-Pentylamino)ethanephosphonic acid;~~

~~(R)-2-(2-Pentylmethylamino)ethanephosphonic acid;~~ and

(R)-2-(2-Heptylamino)ethane-5-tetrazole.

14. (Currently amended) A composition according to claim 11, wherein said compound of formula I is selected from the group consisting of:

(S)-2-(2-Heptylamino)acetic acid;

(S)-2-[N-(2-Heptyl)-N-methylamino]~~)~~acetic acid;

Methyl (S)-2-(2-heptylamino)acetate; and

Methyl (S)-2-[N-(2-heptyl)-N-methylamino]~~)~~acetate~~;~~

~~(S)-2-(2-Heptylamino)acetonitrile;~~

~~(S)-2-(2-Heptylmethylamino)acetonitrile;~~

~~(S)-2-(2-Heptylamino)ethanephosphonic acid; and~~

~~(S) 2-(2-Heptylmethylamino)ethanephosphonic acid~~.

15. (Currently amended) A composition for the treatment ~~or prevention~~ of a disease in which cell death occurs by apoptosis, which composition comprises an effective amount of a compound selected from the group consisting of:

2-[N-(1-Hexyl)-N-methylamino]~~}~~acetic acid;

3-[N-(2-Propyl)-N-methylamino]~~}~~propionic acid;

Methyl 2-[N-(2-Propyl)-N-methylamino]~~}~~acetate;

Methyl 2-[N-(1-Hexyl)-N-methylamino]~~}~~acetate; and

Methyl 3-[N-(1-Hexyl)-N-methylamino]~~}~~propionate~~;~~

~~2-(1-Hexylamino)acetonitrile;~~

~~2-(1-Hexylmethylamino)acetonitrile;~~

~~3-(3-Pentylamino)propionitrile;~~

~~3-(3-Pentylmethylamino)propionitrile;~~

~~2-(2-Propylamino)ethanephosphonic acid; and~~

~~2-(2-Propylmethylamino)ethanephosphonic acid~~

in admixture with a suitable diluent or carrier.

16. (Previously amended) A composition according to claim 11, wherein the compound of formula I is in the form of a hydrochloride salt.

17.-23. (Previously cancelled)

24. (Withdrawn) A commercial package for the treatment or prevention of a disease in which cell death occurs by apoptosis, said package comprising a pharmaceutical composition according claim 11, together with instructions for use in the treatment or prevention of diseases in which cell death occurs by apoptosis.

25. (Currently amended, withdrawn) A method for the treatment ~~or prevention~~ of a disease in which cell death occurs by apoptosis comprising administering an effective amount of a compound of formula I to an animal in need thereof, wherein said formula I:



Formula I

wherein:

R_1 is $(CH_2)_mCH_3$ where m is 0 or an integer in the range from 1 to 16, or an alkenyl, alkynyl, alkoxy, alkylthio, or alkyl sulfinyl group having from 2 to 17 carbon atoms, wherein R_1 may be optionally substituted with one or more substituents selected from hydroxy, aldehyde, oxo, lower acyloxy, halogen, thio, sulfoxide and sulfone,

R_2 = H, CH_3 or CH_2CH_3

R_3 = H or CH_3

R_4 = H or CH_3

R_5 = lower alkyl having 1 to 5 carbon atoms

n is an integer in the range from 1 to 3,

and X is carboxyl (COOH), carbalkoxy ($COOR_5$), cyano ($C\equiv N$), phosphonic acid (PO_3H_2), phosphonate ester ($PO_3[R_5]_2$) or 5-tetrazole, or a pharmaceutically acceptable salt thereof.

26. (Previously added, withdrawn) A method according to claim 25, wherein

R_1 is $(CH_2)_mCH_3$ where m is 0 or an integer in the range from 1 to 16,

R_2 = CH_3,

R_3 = H,

R_4 = H or CH_3,

R_5 = lower alkyl having 1 to 5 carbon atoms,

n is an integer in the range from 1 to 3,

and X is carboxyl (COOH), carbalkoxy ($COOR_5$), cyano (C≡N), phosphonic acid (PO_3H_2), phosphonate ester ($PO_3[R_5]_2$) or 5-tetrazole, or a pharmaceutically acceptable salt thereof.

27. (Previously added, withdrawn) A method according to claim 25 wherein the compound of the Formula I is a substantially pure enantiomer in the R configuration.

28. (Previously added, withdrawn) A method according to claim 25 wherein the compound of the Formula I is a substantially pure enantiomer in the S configuration.

29. (Previously added, withdrawn) A method according to claim 25 wherein said compound of Formula I is selected from the group consisting of:
2-(2-Propylamino)acetic acid;
2-(1-Hexylamino)acetic acid;
(S)-2-(2-Heptylamino)acetic acid;
3-(2-Propylamino)propionic acid;
3-(1-Hexylamino)propionic acid;
(R)-3-(2-Heptylamino)propionic acid;
2-(2-Propylmethylamino)acetic acid;
2-(1-Hexylmethylamino)acetic acid;
(S)-2-(2-Heptylmethylamino)acetic acid;
3-(2-Propylmethylamino)propionic acid;
3-(1-Hexylmethylamino)propionic acid; and
(R)-3-(2-Heptylmethylamino)propionic acid;
2-(2-Propylamino)acetonitrile;
(R)-2-(2-Pentylamino)acetonitrile;
2-(1-Hexylamino)acetonitrile;
(S)-2-(2-Heptylamino)acetonitrile;
(R)-3-(2-Heptylamino)propionitrile;
2-(2-Propylmethylamino)acetonitrile;

(R)-2-(2-Pentylmethylamino)acetonitrile;

2-(1-Hexylmethylamino)acetonitrile;

(S)-2-(2-Heptylmethylamino)acetonitrile;

(R)-3-(2-Heptylmethylamino)propionitrile;

2-(2-Propylamino)ethanephosphonic acid;

(R)-2-(2-Pentylamino)ethanephosphonic acid;

(S)-2-(2-Heptylamino)ethanephosphonic acid;

2-(2-Propylmethylamino)ethanephosphonic acid;

(S)-2-(2-Heptylmethylamino)ethanephosphonic acid; and

(R)-2-(2-Heptylamino)ethane-5-tetrazole.

30.-31. (Cancelled)

32. (Previously presented) A method for the treatment of a disease in which cell death occurs by apoptosis comprising administering an effective amount of a compound of formula I to an animal in need thereof, wherein said compound of formula I is:



Formula I

wherein:

R_1 is $(CH_2)_mCH_3$ where m is 0 or an integer in the range from 1 to 16, or an alkenyl, alkynyl, alkoxy, alkylthio, or alkyl sulfinyl group having from 2 to 17 carbon atoms, wherein R_1 may be optionally substituted with one or more substituents selected from hydroxy, aldehyde, oxo, lower acyloxy, halogen, thio, sulfoxide and sulfone,

R_2 is H, CH_3 or CH_2CH_3,

R_3 is H or CH_3,

R_4 is H or CH_3,

n is an integer in the range from 1 to 3,

and X is carboxyl (COOH), carbalkoxy ($COOR_5$) or 5-tetrazole, and

R_5 is lower alkyl having 1 to 5 carbon atoms,

or a pharmaceutically acceptable salt thereof, and wherein the disease is selected from the group consisting of stroke, head trauma, Bell's palsy, spinal cord injury, Alzheimer's disease, Parkinson's disease, Pick's disease, amyotrophic lateral sclerosis, Huntington's disease, multiple sclerosis, cardiac myopathies, nephropathy, retinopathy, diabetic complications, glaucoma and idiopathic neuropathies.

33. (Previously presented) A method according to claim 32, for the treatment of a human.

34. (New) A method according to claim 32, wherein

R_1 is $(CH_2)_mCH_3$ where m is 0 or an integer in the range from 1 to 16,

R_2 is CH_3,

R_3 is H,

R_4 is H or CH_3,

n is an integer in the range from 1 to 3,

X is carboxyl (COOH), carbalkoxy ($COOR_5$) or 5-tetrazole, and

R_5 is lower alkyl having 1 to 5 carbon atoms,

or a pharmaceutically acceptable salt thereof.

35. (New) A method according to claim 32 wherein said compound of Formula I is selected from the group consisting of:

2-(2-Propylamino)acetic acid;

2-(1-Hexylamino)acetic acid;

(S)-2-(2-Heptylamino)acetic acid;

3-(2-Propylamino)propionic acid;

3-(1-Hexylamino)propionic acid;

(R)-3-(2-Heptylamino)propionic acid;

2-[N-Methyl-N-(2-propyl)amino]acetic acid;

2-[N-(1-Hexyl)-N-methylamino]acetic acid;

(S)-2-[N-(2-Heptyl)-N-methylamino]acetic acid;

3-[N-(2-Propyl)-N-methylamino]propionic acid;

3-[N-(1-Hexyl)-N-methylamino]propionic acid;

(R)-3-[N-(2-Heptyl)-N-methylamino]propionic acid;

and

(R)-2-(2-Heptylamino)ethane-5-tetrazole.